About the Event

Funding for today’s life science ventures is often granted for disruptive innovations that bear intrinsic risks and aim to fundamentally change current healthcare practices. So how do we manage high-risk R&D projects while developing them into a robust pipeline of assets?

At this BioForum, international expert Dr Kurt Stoeckli, President of the NDA Advisory Board (UK), will appear virtually to discuss:

• The key role of risk-based assessment, related mitigation strategies and the importance of early implementation in the development process
• Critical success factors for translating scientific innovation into clinically meaningful milestones
• Strategic considerations for seeking expediting approval and reaching the market in a timely manner
• Early consideration of market access criteria and interactions with regulatory authorities

Exploring the development of novel cancer therapeutics, Oncology One CEO, Dr Joanne Boag, will discuss some of the key challenges and opportunities that exist in the translation of innovative research projects, and what’s needed to unlock the potential of medical research in Australia.

Minomic International CEO, Dr Brad Walsh (Sydney), will also share his insights and some key lessons he has learned through bringing innovations from the lab bench to the marketplace.

Event Details

• Date: Tuesday 22 March 2022
• Time (AEST): 4:00pm to 5:30pm – Presentations and Q&A / 5:30pm to 6:30pm – Networking (in-person guests)
• Venue: Swinburne Studio, ACMI. Federation Square, Melbourne, VIC, 3000
• Live stream: Zoom Webinar. A link to join the event will be shared via a confirmation email 24-48hrs prior to the event.

Run by BioMelbourne Network - Please click here for more information.

---